Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference
September 03 2020 - 8:00AM
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage
biopharmaceutical company, today announced that its president and
chief executive officer, Steven Lo, will present a company overview
at the H.C. Wainwright 22nd Annual Global Investment Conference on
Monday, September 14, 2020 at 1:30 pm ET.
A live webcast of the event will be available on the company’s
website at http://ir.zosanopharma.com/events-presentations. The
archived webcast will remain available for 30 days following the
date of the presentation.
About Zosano PharmaZosano Pharma Corporation is
a clinical-stage biopharmaceutical company focused on developing
products where rapid administration of approved molecules with
established safety and efficacy profiles may provide substantial
benefit to patients, in markets where patients remain underserved
by existing therapies. The company’s transdermal microneedle system
technology consists of titanium microneedles coated with drug that
are designed to enable rapid systemic administration of
therapeutics to patients. Zosano’s lead product candidate is
Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan
delivered via its transdermal microneedle system technology, as an
acute treatment for migraine. The company anticipates that many of
its current and future development programs may enable the company
to utilize a regulatory pathway that has the potential to
streamline clinical development and accelerate the path towards
commercialization. Learn more at www.zosanopharma.com.
Zosano Contact:Christine MatthewsChief
Financial Officer 510-745-1200
PR Contacts:Sylvia Wheeler or Alexandra
Santosswheeler@wheelhouselsa.com or asantos@wheelhouselsa.com
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Apr 2023 to Apr 2024